Biomarker screening for pulmonary hypertension in VLBW infants at risk for bronchopulmonary dysplasia

被引:1
|
作者
Munoz, Fernando A. [1 ]
Kim, Amanda [1 ]
Kelly, Brendan [2 ]
Jackson, Emma Olson [3 ]
Evers, Patrick D. [2 ]
Morrow, Daniel [1 ,4 ]
McCammond, Amy [5 ]
Jordan, Brian K. [1 ]
Scottoline, Brian [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Pediat, Div Neonatol, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Cardiol, Portland, OR USA
[3] Seattle Childrens Hosp, Heart Ctr, Seattle, WA USA
[4] PeaceHlth Sacred Heart Med Ctr Riverbend, Springfield, OR 97477 USA
[5] Univ Calif San Francisco, Dept Pediat, Div Pediat Crit Care, San Francisco, CA USA
关键词
PRETERM INFANTS; NATRIURETIC PEPTIDE; ASSOCIATION; MANAGEMENT; DIAGNOSIS;
D O I
10.1038/s41390-024-03517-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Very low birth weight (VLBW) infants demonstrate altered alveolar and pulmonary vascular development and carry an increased risk of developing bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH). Risk stratification for BPD-associated PH (BPD-PH) in at-risk infants may help tailor management, improve outcomes, and optimize resource utilization. Methods: VLBW infants were screened for PH with blood gas measurements, serum NT-proBNP and bicarbonate (HCO3) levels, and echocardiograms if they remained on respiratory support at 34 weeks corrected gestational age. We then tested 11 models using different cutoffs for NT-proBNP and HCO3 to predict infants at low risk of BPD-PH. Results: We identified PH in 34 of 192 (17.6%) VLBW infants. The median NT-proBNP in VLBWs with PH was 2769 pg/mL versus 917 pg/mL in those without PH (p < 0.0001). A model with NT-proBNP < 950 pg/mL and HCO3 < 32 mmol/L had a sensitivity of 100%, specificity of 34.2%, and negative predictive value of 100%. Using this model, 54 of 192 (28%) of the patients in this study would have been categorized as low risk for PH and could have avoided a screening echocardiogram. Conclusion: NT-proBNP and HCO3 together may serve as sensitive and cost-effective screening tools for BPD-PH in VLBW infants.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] B-type natriuretic peptide is a biomarker for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia
    Cuna, Alain
    Kandasamy, Jegen
    Fineberg, Naomi
    Sims, Brian
    RESEARCH AND REPORTS IN NEONATOLOGY, 2013, 3 : 33 - 36
  • [22] Soluble Klotho, a biomarker and therapeutic strategy to reduce bronchopulmonary dysplasia and pulmonary hypertension in preterm infants
    Batlahally, Sunil
    Franklin, Andrew
    Damianos, Andreas
    Huang, Jian
    Chen, Pingping
    Sharma, Mayank
    Duara, Joanne
    Keerthy, Divya
    Zambrano, Ronald
    Shehadeh, Lina A.
    Martinez, Eliana C.
    DeFreitas, Marissa J.
    Kulandavelu, Shathiyah
    Abitbol, Carolyn L.
    Freundlich, Michael
    Kanashiro-Takeuchi, Rosemeire M.
    Schmidt, Augusto
    Benny, Merline
    Wu, Shu
    Mestan, Karen K.
    Young, Karen C.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [23] Colonisation of the airways with Ureaplasma urealyticum as a risk factor for bronchopulmonary dysplasia in VLBW infants?
    Ruf, B
    Klauwer, D
    Reiss, I
    Schiefer, HG
    Gortner, L
    ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE, 2002, 206 (05): : 187 - 192
  • [24] Developing A Biomarker For Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension
    Bartenschlag, A.
    Zmuda, E.
    Frick, J.
    Gastier-Foster, J.
    Nelin, L. D.
    Trittmann, J. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [25] USE OF SILDENAFIL IN PULMONARY HYPERTENSION (PH) ASSOCIATED WITH BRONCHOPULMONARY DYSPLASIA (BPD) IN VERY LOW BIRTH WEIGHT (VLBW) INFANTS
    Pierro, M.
    Ciarmoli, E.
    Colnaghi, M.
    Colli, A. M.
    Gangi, S.
    Galli, M. A.
    Cecchetti, V.
    Salice, P.
    Schena, F.
    Carpano, F. Maglioli
    Magrini, F.
    Mosca, F.
    INTENSIVE CARE MEDICINE, 2013, 39 : S163 - S163
  • [26] PULMONARY MECHANICS AND CLINICAL COURSE IN VLBW INFANTS WITH BRONCHOPULMONARY DYSPLASIA AFTER CORTICOSTEROID TREATMENT
    HANSSLER, L
    ZHOU, C
    ROLL, C
    WIESEMANN, HG
    KLINISCHE PADIATRIE, 1994, 206 (05): : 372 - 376
  • [27] Risk Factors for Pulmonary Artery Hypertension in Preterm Infants with Moderate or Severe Bronchopulmonary Dysplasia
    Kim, Do-Hyun
    Kim, Han-Suk
    Choi, Chang Won
    Kim, Ee-Kyung
    Kim, Beyong Il
    Choi, Jung-Hwan
    NEONATOLOGY, 2012, 101 (01) : 40 - 46
  • [28] Risk Factors and Outcomes of Pulmonary Hypertension in Infants With Bronchopulmonary Dysplasia: A Meta-Analysis
    Chen, Ying
    Zhang, Di
    Li, Ying
    Yan, Aixia
    Wang, Xiaoying
    Hu, Xiaoming
    Shi, Hangting
    Du, Yue
    Zhang, Wenhui
    FRONTIERS IN PEDIATRICS, 2021, 9
  • [29] Pulmonary Hypertension in Preterm Infants: Prevalence and Association with Bronchopulmonary Dysplasia
    Mirza, Hussnain
    Ziegler, James
    Ford, Sara
    Padbury, James
    Tucker, Richard
    Laptook, Abbot
    JOURNAL OF PEDIATRICS, 2014, 165 (05): : 909 - U338
  • [30] Intermittent Hypoxemia and Bronchopulmonary Dysplasia with Pulmonary Hypertension in Preterm Infants
    Gentle, Samuel J.
    Travers, Colm P.
    Nakhmani, Arie
    Indic, Premananda
    Carlo, Waldemar A.
    Ambalavanan, Namasivayam
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207 (07) : 899 - 907